MREO insider transaction filings
Mereo BioPharma Group plc — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-02-27. Screen MREO transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for MREO between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Mereo BioPharma Group plc
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-02-27 | 4 | Jacquet Pierre — Director | Grant/award (A): 66,000 (derivative) @ $0 · Grant/award (A): 106,848 (derivative) | EDGAR |
| 2026-02-27 | 4 | Bender Jeremy — Director | Grant/award (A): 66,000 (derivative) @ $0 · Grant/award (A): 117,533 (derivative) | EDGAR |
| 2026-02-27 | 4 | Shames Daniel — Director | Grant/award (A): 66,000 (derivative) @ $0 · Grant/award (A): 96,163 (derivative) | EDGAR |
| 2026-02-27 | 4 | Ekblom Anders — Director | Grant/award (A): 66,000 (derivative) @ $0 · Grant/award (A): 133,560 (derivative) | EDGAR |
| 2026-02-27 | 4 | Jenkins Annalisa — Director | Grant/award (A): 66,000 (derivative) @ $0 · Grant/award (A): 106,848 (derivative) | EDGAR |
| 2026-02-27 | 4 | Yoskowitz Marc J — Director | Grant/award (A): 66,000 (derivative) @ $0 · Grant/award (A): 96,163 (derivative) | EDGAR |
| 2026-02-27 | 4 | PAKIANATHAN DEEPIKA — Director | Grant/award (A): 66,000 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | WYZGA MICHAEL S — Director | Grant/award (A): 66,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Hughes-Wilson Alexandra — See Remarks | Grant/award (A): 183,750 (derivative) @ $0 · Grant/award (A): 61,250 (derivative) @ $0 · Grant/award (A): 195,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Fox Christine Ann — Chief Financial Officer | Grant/award (A): 315,750 (derivative) @ $0 · Grant/award (A): 105,250 (derivative) @ $0 · Grant/award (A): 280,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Sermon Charles — General Counsel | Grant/award (A): 315,750 (derivative) @ $0 · Grant/award (A): 105,250 (derivative) @ $0 · Grant/award (A): 295,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Lewicki John A. — Chief Scientific Officer | Grant/award (A): 139,913 (derivative) @ $0 · Grant/award (A): 46,637 (derivative) @ $0 · Grant/award (A): 145,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Scots-Knight Denise — Chief Executive Officer, Director | Grant/award (A): 1,035,000 (derivative) @ $0 · Grant/award (A): 345,000 (derivative) @ $0 · Grant/award (A): 480,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Bender Jeremy — Director | Grant/award (A): 55,000 (derivative) @ $0 · Grant/award (A): 16,768 (derivative) | EDGAR |
| 2025-02-06 | 4 | Shames Daniel — Director | Grant/award (A): 55,000 (derivative) @ $0 · Grant/award (A): 13,719 (derivative) | EDGAR |
| 2025-02-06 | 4 | Jacquet Pierre — Director | Grant/award (A): 55,000 (derivative) @ $0 · Grant/award (A): 15,243 (derivative) | EDGAR |
| 2025-02-06 | 4 | Ekblom Anders — Director | Grant/award (A): 55,000 (derivative) @ $0 · Grant/award (A): 19,054 (derivative) | EDGAR |
| 2025-02-06 | 4 | Jenkins Annalisa — Director | Grant/award (A): 55,000 (derivative) @ $0 · Grant/award (A): 15,243 (derivative) | EDGAR |
| 2025-02-06 | 4 | Yoskowitz Marc J — Director | Grant/award (A): 55,000 (derivative) @ $0 · Grant/award (A): 13,719 (derivative) | EDGAR |
| 2025-02-06 | 4 | PAKIANATHAN DEEPIKA — Director | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | WYZGA MICHAEL S — Director | Grant/award (A): 55,000 (derivative) @ $0 · Grant/award (A): 30,487 (derivative) | EDGAR |
| 2025-01-28 | 4 | Fox Christine Ann — Chief Financial Officer | Grant/award (A): 262,000 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Hughes-Wilson Alexandra — See Remarks | Grant/award (A): 154,000 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Sermon Charles — General Counsel | Grant/award (A): 262,000 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Lewicki John A. — Chief Scientific Officer | Grant/award (A): 116,000 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Scots-Knight Denise — Chief Executive Officer | Grant/award (A): 825,000 (derivative) @ $0 | EDGAR |
| 2024-09-16 | 4 | Fox Christine Ann — Chief Financial Officer | Sale (S): 9,128 @ $4.47 · Sale (S): 19,158 @ $4.22 | EDGAR |
| 2024-09-16 | 4 | Hughes-Wilson Alexandra — See Remarks | Sale (S): 7,769 @ $4.47 · Sale (S): 40,029 @ $4.47 · Sale (S): 16,304 @ $4.22 · Sale (S): 84,008 @ $4.22 | EDGAR |
| 2024-09-16 | 4 | Sermon Charles — General Counsel | Sale (S): 9,980 @ $4.47 · Sale (S): 20,946 @ $4.22 | EDGAR |
| 2024-09-16 | 4 | Lewicki John A. — Chief Scientific Officer | Sale (S): 5,212 @ $4.47 · Sale (S): 10,937 @ $4.22 | EDGAR |
| 2024-09-16 | 4 | Scots-Knight Denise — Chief Executive Officer, Director | Sale (S): 28,611 @ $4.47 · Sale (S): 60,046 @ $4.22 | EDGAR |
| 2024-09-13 | 4 | Fox Christine Ann — Chief Financial Officer | Option exercise (M): 60,000 @ $0 · Option exercise (M): 60,000 (derivative) @ $0 | EDGAR |
| 2024-09-13 | 4 | Hughes-Wilson Alexandra — See Remarks | Option exercise (M): 40,000 @ $0 · Option exercise (M): 93,333 @ $1.40 · Option exercise (M): 75,000 @ $1.01 · Option exercise (M): 40,000 (derivative) @ $0 · Option exercise (M): 93,333 (derivative) @ $1.40 · Option exercise (M): 75,000 (derivative) @ $1.01 | EDGAR |
| 2024-09-13 | 4 | Sermon Charles — General Counsel | Option exercise (M): 65,600 @ $0 · Option exercise (M): 65,600 (derivative) @ $0 | EDGAR |
| 2024-09-13 | 4 | Lewicki John A. — Chief Scientific Officer | Option exercise (M): 46,000 @ $0 · Option exercise (M): 46,000 (derivative) @ $0 | EDGAR |
| 2024-09-13 | 4 | Scots-Knight Denise — Chief Executive Officer, Director | Option exercise (M): 188,060 @ $0 · Option exercise (M): 188,060 (derivative) @ $0 | EDGAR |
| 2024-08-23 | 4 | PAKIANATHAN DEEPIKA — Director | Option exercise (M): 1,825 @ $3 · Option exercise (M): 6,492 @ $1.84 · Option exercise (M): 12,418 @ $2.72 · Option exercise (M): 38,953 @ $1.31 · Option exercise (M): 43,485 @ $0.94 · Option exercise (M): 2,071 @ $3.87 · +7 more | EDGAR |
| 2024-06-27 | 4 | Fox Christine Ann — Chief Financial Officer | Sale (S): 12,990 @ $3.69 · Sale (S): 29,439 @ $3.39 | EDGAR |
| 2024-06-27 | 4 | Hughes-Wilson Alexandra — See Remarks | Sale (S): 10,134 @ $3.69 · Sale (S): 22,968 @ $3.39 | EDGAR |
| 2024-06-27 | 4 | Sermon Charles — General Counsel | Sale (S): 14,202 @ $3.69 · Sale (S): 32,187 @ $3.39 | EDGAR |
| 2024-06-27 | 4 | Lewicki John A. — Chief Scientific Officer | Sale (S): 7,416 @ $3.69 · Sale (S): 16,808 @ $3.39 | EDGAR |
| 2024-06-27 | 4 | Scots-Knight Denise — Chief Executive Officer, Director | Sale (S): 40,712 @ $3.69 · Sale (S): 92,273 @ $3.39 | EDGAR |
| 2024-06-25 | 4 | Fox Christine Ann — Chief Financial Officer | Option exercise (M): 90,000 @ $0 · Option exercise (M): 90,000 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | Hughes-Wilson Alexandra — See Remarks | Option exercise (M): 60,000 @ $0 · Option exercise (M): 60,000 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | Sermon Charles — General Counsel | Option exercise (M): 98,400 @ $0 · Option exercise (M): 98,400 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | Lewicki John A. — Chief Scientific Officer | Option exercise (M): 69,000 @ $0 · Option exercise (M): 69,000 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | Scots-Knight Denise — Chief Executive Officer, Director | Option exercise (M): 282,090 @ $0 · Option exercise (M): 282,090 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Bender Jeremy — Director | Grant/award (A): 12,550 @ $3.99 | EDGAR |
| 2024-06-17 | 4 | Rubric Capital Management LP — 10% owner Rosen David Efraim — 10% owner | Grant/award (A): 1,754,350 (derivative) @ $3.99 | EDGAR |
| 2024-06-17 | 4 | WYZGA MICHAEL S — Director | Grant/award (A): 25,050 @ $3.99 | EDGAR |
Recent 8-K events — Mereo BioPharma Group plc
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-19 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-08-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K/A | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-19 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-17 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MREO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →